Albumin-targeted oxaliplatin(iv) prodrugs bearing STING agonists.

ABSTRACT: The anticancer platinum complex oxaliplatin exerts its activity through DNA damage and immune-stimulatory mechanisms, but is associated with adverse treatment side effects. Platinum(iv) complexes represent a promising prodrug strategy to improve tolerability and to enhance antitumor efficacy via attachment of additional bioactive ligands or tumor-targeting moieties. In the present study, oxaliplatin(iv) complexes containing immune-stimulatory STING agonists SR-717 or MSA-2 were synthesized and their biological properties were studied. Whereas the Pt-SR-717 compound was fast reduced, Pt-MSA-2 complexes displayed significantly higher reductive stability reflected by low in vitro cytotoxicity. Although the platinum(iv) complexes activated interferon regulatory factor (IRF) and N

SUBMITTER: Dijkstra M 

PROVIDER: S-EPMC11969438 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature